查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863477

腫瘤精準醫療市場（依治療方法、癌症類型、技術、生物標記類型和最終用戶分類）－2025-2032年全球預測

Oncology Precision Medicine Market by Therapy Type, Cancer Type, Technology, Biomarker Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腫瘤精準醫療市場將成長至 166.4 億美元，複合年成長率為 10.16%。

關鍵市場統計數據
基準年 2024 76.7億美元
預計年份：2025年 84.3億美元
預測年份 2032 166.4億美元
複合年成長率 (%) 10.16%

一份策略性入門指南，闡述診斷創新、治療方法進展和數據整合如何重新定義精準腫瘤學的臨床路徑和商業性模式。

精準腫瘤學正處於一個轉折點，治療方法、診斷技術和數據分析的進步正在融合，重塑臨床決策和商業策略。免疫療法、標靶藥物和分子診斷的最新創新，正將重點從「一刀切」的治療模式轉向精準的患者照護路徑，這需要新的證據生成模型，以及臨床、監管和支付方等相關人員之間更緊密的合作。

本導言概述了變革的關鍵促進因素，概述了對開發商和供應商的實際意義，並為後續章節提供了框架，這些章節將探討結構性轉變、與關稅相關的供應鏈風險以及特定領域的動態。相關人員面臨日益複雜的局面：多重檢測和次世代定序結果可即時指導治療方案的選擇，伴隨診斷組合在臨床試驗設計和產品定位中也變得越來越重要。

此外，隨著醫療服務日益分散化，診斷實驗室和門診機構也開始採用以往僅限於三級醫療中心的技術。對整合營運規劃、跨職能協作和資料互通性的投資，對於從概念驗證過渡到可擴展的實施至關重要。後續分析揭示了組織重點關注哪些領域最有可能帶來持續的臨床和商業性優勢。

治療方法的進步、診斷多重化以及支付方期望的改變，都要求在癌症治療的開發和實施過程中採取綜合策略方法。

精準癌症醫學領域正經歷著一場變革性的轉變，其驅動力包括科技的成熟、監管環境的演變以及相關人員期望的改變。免疫療法，例如CAR-T細胞療法和查核點抑制劑，正從新興療法發展成為治療流程中的關鍵組成部分，重新​​定義了骨髓惡性腫瘤和某些固態腫瘤的治療結果。同時，以單株抗體和小分子抑制劑形式遞送的標靶治療，透過不斷改進的標靶檢驗和持續發展的抗藥性管理策略，也不斷提高治療效果。

診斷技術已從單分析物檢測發展到多重檢測平台。雖然免疫組織化學和螢光雜合反應仍然是基礎技術，但聚合酵素鏈鎖反應(PCR) 檢測和次世代定序技術能夠以臨床可操作的深度進行廣泛的基因組分析。診斷技術的擴展有助於對常見癌症類型進行更精確的分層，使臨床醫生能夠更有把握地根據腫瘤生物學特徵制定治療方法。

在商業方面，支付者和醫療保健系統要求提供更有力的臨床效用和真實世界療效證據，迫使申辦方設計適應性試驗框架和核准後證據計畫。診斷提供者和藥物研發商之間的合作日益增多，聯合開發和打包報銷模式也變得越來越普遍。總而言之，這些變化凸顯了製定整合式臨床開發策略的重要性，該策略需預見監管預期和醫療服務體系的限制。

評估新關稅政策對精準腫瘤學領域供應鏈、實驗室運作和臨床專案韌性的營運和策略影響

2025年實施的新關稅政策增加了精準腫瘤學生態系統的運作複雜性，影響了試劑、儀器組件和生物製品生產的供應鏈。單株抗體、細胞治療材料和定序平台的生產商面臨某些進口原料和儀器組件更高的到岸成本，迫使他們重新評估籌資策略和庫存管理實務。

這些與關稅相關的壓力也對臨床開發和實驗室運作產生了連鎖反應。依賴進口耗材的診斷實驗室面臨更長的採購前置作業時間和更大的成本波動，這可能會擾亂檢測標準化和實驗室認證的進度。進行全球臨床試驗的申辦者必須考慮區域成本差異和臨床實驗藥物供應可能中斷的情況，這會影響研究中心的選擇和研究物流。

為因應這項挑戰，各組織正致力於供應商多元化，盡可能優先選擇國內製造夥伴關係，並重新設計包裝和運輸方式，以減少對關稅敏感品類的依賴。監理申報和品質管理系統必須包含供應商替換的緊急時應對計畫，合約團隊也正在與供應商協商更靈活的條款。儘管關稅帶來了巨大的執行風險，但它也加速了對區域分散式製造能力的投資，並推動建立強大的供應鏈網路，以確保治療和診斷產品的持續供應。

基於細分的治療類別、癌症類型、診斷技術、生物標記分類和最終用戶採用情況的洞察，可指導優先排序。

基於細緻細分的分析突顯了價值創造和營運重點領域。就治療方法類型而言，荷爾蒙療法仍然是多種治療途徑的基礎；免疫療法涵蓋了CAR-T細胞療法等細胞療法和全身性查核點抑制劑；標靶治療涵蓋了單株抗體和小分子抑制劑。每種治療類別都有其獨特的研發、生產和商業化考量，這些都會影響跨職能規劃。

按癌症類型細分，突顯了每種疾病領域獨特的臨床和診斷需求。乳癌、大腸癌、肺癌、黑色素瘤和攝護腺癌各自擁有獨特的生物標記譜、不同的標準治療方案，以及支付者對先進診斷和聯合治療的報銷意願。針對每種腫瘤類型的自然病程和治療模式，制定相應的臨床證據策略，可以提高診斷和治療方案組合的有效性。

技術細分將支撐現代診斷的調查方法進行分類，包括螢光原位雜合反應、免疫組織化學、次世代定序和聚合酵素鏈鎖反應。每種技術在靈敏度、通量、週轉時間和操作規模方面各有優劣，決定了其實際應用場景。依生物標記類型細分，涵蓋表觀遺傳學、遺傳學和蛋白質檢測，可進一步細化檢測對治療決策和監管路徑的影響程度。

按最終用戶進行細分有助於明確產品採納和商業化路徑。門診中心、診所、診斷實驗室和醫院的資金資源、工作流程整合能力和報銷編碼方式各不相同。使產品設計和服務模式與這些最終用戶的營運實際情況相匹配，有助於加快產品採納和更順利地實施。總而言之，這種多層次細分方法有助於更精準地確定投資優先順序、產生證據並最佳化產品上市時間。

區域比較分析突顯了關鍵區域在採納率、報銷和基礎設施方面的差異如何導致精準癌症治療策略的差異化。

區域趨勢正在影響精準癌症治療生態系統的應用模式和策略重點。在美洲，創新中心和完善的臨床基礎設施支持先進治療方法和全面基因組分析的快速應用，而支付方環境和報銷途徑的差異則要求制定針對國家和地方市場的循證方案和支付方參與策略。

歐洲、中東和非洲地區（EMEA）監管環境的差異以及獲得專科醫療服務的不平等，正在影響診斷技術和新療法的引入。歐洲部分地區的集中式衛生技術評估（HTA）機制著重於療效比較和成本效益，而中東某些市場則正在為先進的細胞療法和精準診斷奠定基礎。在非洲部分地區，有限的檢測基礎設施和薄弱的供應鏈需要專門的模式來實現分散式檢查和永續的試劑供應。

亞太地區擁有成熟的大都會圈和快速發展的醫療保健體系。多個市場正在大力投資高通量定序技術和本土生物製藥生產，這為區域供應夥伴關係和本地化臨床開發創造了機會。同時，監管協調和不斷變化的報銷標準要求制定靈活的准入策略，以加快患者獲得治療，同時滿足當地的循證醫學要求。在所有地區，相關人員必須將全球產品策略與當地細緻入微的營運和監管實際情況相協調。

策略聯盟、平台投資以及關鍵參與者之間的垂直整合如何重塑精準癌症治療領域的競爭格局和價值獲取方式

治療、診斷和綜合服務領域的領導企業正透過策略聯盟、平台投資和垂直整合重塑競爭動態。生物製藥企業正日益與診斷開發商合作，共同設計伴隨檢測和並行證據生成項目，以支持監管申報和與支付方的溝通。診斷實驗室和設備供應商正投資於自動化和數位化報告，以擴大高複雜度檢測的規模，同時提高檢測的可重複性和周轉時間。

為了滿足日益成長的複雜治療方法需求，供應鏈合作夥伴和契約製造正在擴展其細胞療法支援服務以及生物製藥填充和最終包裝能力。科技公司正在採用雲端基礎的分析和機器學習技術，以提高變異解讀的準確性，並為臨床醫生開發決策支援工具，將定序結果轉化為可操作的見解。這些發展正在影響策略聯盟、併購活動以及優選供應商網路的形成。

能夠證明其在整個生態系統中端到端地整合了強大的分析有效性、臨床效用和切實可行的實施支持價值的公司，將更有利於在醫療服務提供者網路中獲得更廣泛的認可，並與支付方實現有效的合作。在中短期內，卓越的生產運作、對監管法規的深刻理解以及提供真實世界證據的能力，將使行業領導者脫穎而出，區別於追隨者。

為整合診斷技術開發、供應鏈韌性和實證實踐，以加速其應用和獲得支付方認可，提出切實可行且影響深遠的建議。

行業領導者應採取果斷措施，協調臨床開發、診斷策略和商業性化實施，確保治療進展能夠轉化為持續的患者獲益和永續的商業成果。優先事項包括將伴隨診斷的開發更早納入治療生命週期，這將降低監管風險，並為支付方和醫療服務提供者創造更清晰的價值提案。領導者應透過供應商多元化、盡可能採用雙重採購以及對區域製造能力進行策略性投資來增強供應鏈韌性。

在營運方面，各機構必須投資於可互通的資料平台和證據生成框架，以支持快速累積真實世界的結果。加強與診斷實驗室和醫療服務機構的合作將加速技術的應用，尤其是在明確定義實施流程和報銷途徑的情況下。同時，商業部門應針對每種癌症類型，建構反映其獨特臨床背景和所採用診斷技術的客製化衛生經濟學敘事。

最後，建構整合監管、臨床、商業和供應鏈決策的跨職能管治，可降低實施風險，並改善上市前後各項活動的協調。透過優先進行這些工作，領導者將更有能力在應對監管複雜性、支付方審查和營運中斷的同時，實現患者照護的可衡量改善。

採用穩健的多方法調查方法，結合專家訪談、監管和臨床證據審查以及情境分析，以支持實用見解。

這項綜合研究採用多方面方法，旨在捕捉精準腫瘤學領域的技術、臨床、監管和營運發展。透過對臨床意見領袖、實驗室主任和供應鏈高管的訪談，我們獲得了關於檢測應用和治療部署實際操作情況的定性見解。這些一線觀點與已發布的監管決策、同行評審的臨床文獻和技術產品文件進行交叉驗證，以確保其符合最新的臨床和技術標準。

對診斷工作流程、技術應用案例和支付方政策聲明的二次分析，指導了部署限制和報銷促進因素的評估。情境分析用於對供應鏈脆弱性進行壓力測試，並識別各組織目前實施的切實可行的緩解措施。我們的調查方法強調資訊來源的透明度和對定性資料的謹慎解讀，著重於可觀察的趨勢和已記錄的政策變化，而非推測性的預測。

在整個研究過程中，我們力求從多個相關人員取得證據，並在缺乏共識之處探討不同觀點。這種混合方法框架旨在為決策者提供平衡且切實可行的策略和營運選擇視角，這些選擇將影響未來精準癌症治療的發展方向。

策略結論強調了診斷、治療研發和穩健運作的整合，以確保患者療效的持續性和商業性成功。

總之，精準腫瘤學正邁入一個以整合診斷、特異性治療方法策略以及對真實世界證據日益成長的需求為特徵的新時代。免疫療法、標靶治療和先進診斷平台之間的相互作用正迫使相關人員重新思考研發範式、商業模式和營運基礎設施。那些能夠將伴隨診斷研發與治療方案同步推進、建立穩健的供應鏈網路並投資於可互通數據系統的機構，將更有能力將科學進步轉化為持續的臨床獲益。

關稅相關的供應風險和區域間准入環境的差異凸顯了製定靈活、本地化策略的必要性。透過優先考慮跨職能管治和儘早與支付方接洽，申辦方和服務供應商可以降低推廣障礙，加速創新成果轉化為常規實踐。將嚴謹的科學研究與切實可行的營運設計相結合，高效、永續地將有前景的治療方法提供給合適的患者，將是未來成功的關鍵。

綜上所述，這些結論為希望清晰、有目標地駕馭不斷發展的精準癌症治療生態系統的相關人員提供了策略基礎。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將液態生物檢體檢測整合到臨床工作流程中，用於腫瘤的早期檢測和監測
  • 利用人工智慧驅動的基因組數據分析平台實現腫瘤免疫療法的個人化治療
  • 癌症類型無關藥物核准的出現：針對特定基因突變，適用於多種癌症類型
  • 整合多體學學分析以最佳化患者分層和治療選擇。
  • 開發靶向新型腫瘤抗原且具有更高特異性的抗體藥物複合體
  • 利用新一代工程技術拓展CAR-T細胞療法在固體癌的應用
  • 利用電子健康記錄中的真實世界證據改進精準醫療策略

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 腫瘤精準醫療市場（依治療方法）

  • 荷爾蒙療法
  • 免疫療法
    • CAR-T細胞療法
    • 查核點抑制劑
  • 標靶治療
    • 單株抗體
    • 小分子抑制劑

第9章 按癌症類型分類的腫瘤精準醫療市場

  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 黑色素瘤
  • 攝護腺癌

10. 按技術分類的腫瘤精準醫療市場

  • FISH
  • 免疫組織化學（IHC）
  • 次世代定序
  • PCR

第11章：以生物標記類型分類的腫瘤精準醫療市場

  • 表觀遺傳學檢測
  • 基因檢測
  • 蛋白質檢測

第12章：依最終用戶分類的腫瘤精準醫療市場

  • 門診治療中心
  • 診所
  • 診斷實驗室
  • 醫院

第13章：腫瘤精準醫療市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 腫瘤精準醫療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國腫瘤精準醫療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd.
    • Illumina, Inc.
    • QIAGEN NV
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • PerkinElmer, Inc.
    • Guardant Health, Inc.
Product Code: MRR-5C6F41F5B030

The Oncology Precision Medicine Market is projected to grow by USD 16.64 billion at a CAGR of 10.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.67 billion
Estimated Year [2025] USD 8.43 billion
Forecast Year [2032] USD 16.64 billion
CAGR (%) 10.16%

A strategic primer introducing how diagnostic innovation, therapeutic evolution, and data integration are jointly redefining precision oncology clinical pathways and commercial approaches

Precision oncology stands at an inflection point as converging advances in therapeutics, diagnostics, and data analytics reshape clinical decision making and commercial strategy. Recent innovations in immunotherapy modalities, targeted agents, and molecular diagnostics have shifted the emphasis from one-size-fits-all approaches to finely stratified patient care pathways, demanding new evidence-generation models and closer alignment across clinical, regulatory, and payer stakeholders.

This introduction synthesizes the principal drivers of change, outlines the practical implications for developers and providers, and frames the subsequent sections that probe structural shifts, tariff-related supply chain risks, and segmentation-specific dynamics. Stakeholders face accelerating complexity: multiplex assays and next-generation sequencing outputs are informing therapy selection in real time, and companion diagnostic pairing is increasingly integral to clinical trial design and product positioning.

Moreover, as care delivery becomes more decentralized, diagnostic laboratories and ambulatory settings are adopting technologies that were once confined to tertiary centers. Transitioning from proof-of-concept to scalable implementation requires integrated operational plans, cross-functional collaboration, and investment in data interoperability. The subsequent analysis highlights where organizational focus is most likely to yield durable clinical and commercial advantage.

How converging therapeutic advances, diagnostic multiplexing, and evolving payer expectations are forcing integrated strategic approaches across oncology development and delivery

The landscape of precision oncology is undergoing transformative shifts driven by technological maturation, regulatory evolution, and changing stakeholder expectations. Immunotherapies such as CAR T-cell interventions and checkpoint inhibitors have moved from novelty to essential components of treatment algorithms, redefining outcomes in hematologic malignancies and selected solid tumors. Concurrently, targeted therapies delivered as monoclonal antibodies or small molecule inhibitors continue to refine therapeutic windows through improved target validation and resistance management strategies.

Diagnostics have evolved from single-analyte tests to multiplexed platforms; immunohistochemistry and fluorescence in situ hybridization remain foundational, while polymerase chain reaction assays and next-generation sequencing now enable broader genomic profiling at clinically actionable depth. This diagnostic breadth supports more precise stratification across common cancer types, allowing clinicians to match interventions to tumor biology with greater confidence.

Commercially, payers and health systems are demanding stronger evidence of clinical utility and real-world benefit, prompting sponsors to design adaptive trial frameworks and post-approval evidence programs. Partnerships between diagnostics providers and pharmaceutical developers are expanding, with co-development and bundled reimbursement models gaining traction. Taken together, these shifts elevate the importance of integrated clinical development strategies that anticipate regulatory expectations and delivery system constraints.

Assessing the operational and strategic consequences of new tariff policies on supply chains, laboratory operations, and clinical program resilience across precision oncology

The introduction of new tariff policies in 2025 has introduced additional layers of operational complexity across the precision oncology ecosystem, affecting supply chains for reagents, instrument components, and biologic production inputs. Manufacturers of monoclonal antibodies, cell-therapy materials, and sequencing platforms face higher landed costs for certain imported raw materials and instrument subassemblies, prompting reassessments of sourcing strategies and inventory practices.

These tariff-related pressures have ripple effects through clinical development and laboratory operations. Diagnostic laboratories reliant on imported consumables may encounter longer procurement lead times and greater cost volatility, which can complicate assay standardization and laboratory accreditation timelines. Clinical trial sponsors operating global studies must now account for variable local costs and potential disruptions to investigational product supply, influencing site selection and trial logistics.

In response, organizations are intensifying efforts to diversify supplier bases, prioritize domestic manufacturing partnerships where feasible, and redesign packaging and shipment practices to reduce exposure to tariff-sensitive categories. Regulatory submissions and quality programs must incorporate contingency planning for supplier substitutions, and contracting teams are negotiating more flexible terms with vendors. While tariffs present material execution risks, they are also accelerating investments in regionalized manufacturing capacity and robust supply network mapping to preserve continuity in both therapeutic and diagnostic delivery.

Segmentation-driven insights that delineate therapeutic categories, cancer types, diagnostic technologies, biomarker classes, and end-user deployment realities to guide prioritization

A careful segmentation-driven lens clarifies where value is created and where operational attention is required. When considering therapy type, hormonal treatments continue to anchor several care pathways, immunotherapies encompass both cellular approaches such as CAR T-cell therapy and systemic checkpoint inhibitors, and targeted therapy spans monoclonal antibodies as well as small molecule inhibitors; each therapeutic category carries distinct development, manufacturing, and commercialization considerations that influence cross-functional planning.

Cancer-type segmentation highlights the divergent clinical and diagnostic needs across disease areas: breast cancer, colorectal cancer, lung cancer, melanoma, and prostate cancer each present unique biomarker landscapes, differing standard-of-care backdrops, and variable payer willingness to reimburse advanced diagnostics and combination regimens. Tailoring clinical evidence strategies to the natural history and treatment paradigms of each tumor type enhances the relevance of diagnostic-therapeutic pairings.

Technology segmentation separates the methodological approaches that underpin contemporary diagnostics, including fluorescence in situ hybridization, immunohistochemistry, next-generation sequencing, and polymerase chain reaction. Each technology offers trade-offs across sensitivity, throughput, turnaround time, and operational footprint, influencing which settings can realistically adopt them. Biomarker-type segmentation-covering epigenetic testing, genetic testing, and protein testing-further refines where assays will impact treatment decisions and regulatory pathways.

End-user segmentation clarifies deployment and commercialization pathways: ambulatory care centers, clinics, diagnostic laboratories, and hospitals differ in capital capacity, workflow integration capability, and reimbursement coding practices. Aligning product design and service models to the operational realities of these end users supports faster adoption and smoother implementation. Collectively, this layered segmentation approach supports more precise prioritization of investment, evidence generation, and go-to-market sequencing.

Comparative regional analysis highlighting how adoption, reimbursement, and infrastructure differences across major geographies drive differentiated precision oncology strategies

Regional dynamics are shaping both adoption patterns and strategic priorities across the precision oncology ecosystem. In the Americas, innovation hubs and extensive clinical infrastructure support rapid uptake of advanced therapeutics and comprehensive genomic profiling, yet divergent payer environments and reimbursement pathways require targeted evidence planning and payer engagement strategies tailored to national and subnational markets.

Within Europe, the Middle East & Africa, heterogeneous regulatory landscapes and variable access to specialized care influence how diagnostics and novel therapies are introduced. Centralized health technology assessment mechanisms in parts of Europe emphasize comparative effectiveness and cost-effectiveness, while select markets in the Middle East are building capacity for advanced cell therapies and precision diagnostics. In parts of Africa, constrained laboratory infrastructure and supply chain fragility necessitate tailored models for decentralized testing and durable reagent supply.

The Asia-Pacific region presents a spectrum of mature metropolitan centers alongside rapidly developing healthcare systems. High-throughput sequencing adoption and investments in domestic biologics manufacturing are notable in several markets, creating opportunities for regional supply partnerships and localized clinical development. At the same time, regulatory harmonization and variable reimbursement criteria require flexible access strategies that can accelerate patient access while meeting local evidence requirements. Across regions, stakeholders must reconcile global product strategies with nuanced local operational and regulatory realities.

How strategic alliances, platform investments, and vertical integration among leading players are reshaping competitive dynamics and value capture in precision oncology

Leading organizations in therapeutics, diagnostics, and integrated service provision are reshaping competitive dynamics through strategic alliances, platform investments, and vertical integration. Biopharmaceutical sponsors are increasingly collaborating with diagnostic developers to co-design companion assays and parallel evidence-generation programs that support regulatory filings and payer conversations. Diagnostic laboratories and instrument providers are investing in automation and digital reporting to scale high-complexity testing while improving reproducibility and turnaround times.

Supply chain partners and contract manufacturers are expanding capabilities in cell-therapy support services and biologics fill-finish operations to meet rising demand for complex modalities. Technology companies are deploying cloud-based analytics and machine learning to enhance variant interpretation and to create clinician-facing decision support tools that translate sequencing outputs into actionable insights. These moves are influencing strategic partnerships, M&A activity, and the formation of preferred supplier networks.

Across the ecosystem, firms that can demonstrate end-to-end value-linking robust analytical validity, clinical utility, and practical implementation support-are positioned to secure stronger adoption in provider networks and to engage more effectively with payers. Operational excellence in manufacturing, regulatory acumen, and the capacity to deliver real-world evidence will distinguish leaders from followers in the near to medium term.

Practical and high-impact recommendations for leaders to integrate diagnostic-development, supply resilience, and evidence generation to accelerate adoption and payer acceptance

Industry leaders should take decisive steps to align clinical development, diagnostic strategy, and commercial implementation so that therapeutic advances translate into durable patient benefit and sustainable business outcomes. Priorities include embedding companion diagnostic development early in the therapeutic lifecycle to de-risk regulatory pathways and to create clearer value propositions for payers and providers. Leaders should reinforce supply chain resilience through supplier diversification, dual sourcing where feasible, and strategic investments in regional manufacturing capabilities.

Operationally, organizations must invest in interoperable data platforms and evidence-generation frameworks that support rapid accumulation of real-world outcomes. Strengthening collaborations with diagnostic laboratories and care delivery settings will accelerate adoption, particularly when implementation workflows and reimbursement pathways are clearly addressed. In parallel, commercial teams should develop tailored health-economic narratives that reflect the specific clinical contexts of each cancer type and the diagnostic technologies employed.

Finally, fostering cross-functional governance that integrates regulatory, clinical, commercial, and supply chain decision-making will reduce time-to-adoption risks and improve alignment across launch and post-launch activities. By prioritizing these actions, leaders will be better positioned to navigate regulatory complexity, payer scrutiny, and operational disruption while delivering measurable improvements in patient care.

Robust multi-method research methodology combining expert interviews, regulatory and clinical evidence review, and scenario analysis to underpin actionable insights

The research behind this synthesis integrates a multi-method approach to capture technological, clinical, regulatory, and operational developments across precision oncology. Primary interviews with clinical thought leaders, laboratory directors, and supply chain executives provided qualitative insights into the operational realities of assay implementation and therapeutic deployment. These firsthand perspectives were triangulated with public regulatory decisions, peer-reviewed clinical literature, and technical product documentation to ensure alignment with the latest clinical and technological standards.

Secondary analysis of diagnostic workflows, technology adoption case studies, and payer policy statements informed the assessment of deployment constraints and reimbursement drivers. Scenario analysis was applied to stress-test supply chain vulnerabilities and to identify pragmatic mitigation steps that organizations are currently implementing. The methodology emphasizes transparency in source attribution and conservative interpretation of qualitative inputs, focusing on observable trends and documented policy shifts rather than speculative projections.

Throughout the research process, efforts were made to corroborate findings across multiple stakeholders and to surface divergent perspectives where consensus is lacking. This mixed-methods framework is intended to provide decision-makers with a balanced, actionable view of the strategic and operational choices that will shape precision oncology over the near term.

Synthesis of strategic conclusions emphasizing integration of diagnostics, therapy development, and resilient operations to secure durable patient and commercial outcomes

In conclusion, precision oncology is transitioning into an era defined by integrated diagnostics, modality-specific therapeutic strategies, and heightened expectations for real-world evidence. The interplay between immunotherapies, targeted agents, and advanced diagnostic platforms is prompting stakeholders to rethink development paradigms, commercial models, and operational infrastructure. Organizations that synchronize companion diagnostic development with therapeutic programs, build resilient supply networks, and invest in interoperable data systems will be better equipped to translate scientific advances into consistent clinical benefit.

Tariff-related supply risks and varied regional access environments underscore the need for flexible, regionally informed strategies. By prioritizing cross-functional governance and early payer engagement, sponsors and service providers can mitigate adoption barriers and accelerate the translation of innovations into standard practice. The path forward favors those who combine scientific rigor with pragmatic operational design, ensuring that promising therapies reach the right patients efficiently and sustainably.

Taken together, these conclusions provide a strategic foundation for stakeholders seeking to navigate the evolving precision oncology ecosystem with clarity and purpose.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of liquid biopsy assays into clinical workflows for early tumor detection and monitoring
  • 5.2. Adoption of AI-driven genomic data analysis platforms to personalize immuno-oncology therapies
  • 5.3. Emergence of tumor-agnostic drug approvals targeting specific genetic alterations across cancer types
  • 5.4. Integration of multiomics profiling for more precise patient stratification and therapy selection
  • 5.5. Development of antibody-drug conjugates targeting novel tumor antigens with enhanced specificity
  • 5.6. Expansion of CAR-T cell therapies into solid tumors through next-generation engineering approaches
  • 5.7. Utilization of real-world evidence from electronic health records to refine precision medicine strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology Precision Medicine Market, by Therapy Type

  • 8.1. Hormonal Therapy
  • 8.2. Immunotherapy
    • 8.2.1. CAR T-Cell Therapy
    • 8.2.2. Checkpoint Inhibitors
  • 8.3. Targeted Therapy
    • 8.3.1. Monoclonal Antibodies
    • 8.3.2. Small Molecule Inhibitors

9. Oncology Precision Medicine Market, by Cancer Type

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Lung Cancer
  • 9.4. Melanoma
  • 9.5. Prostate Cancer

10. Oncology Precision Medicine Market, by Technology

  • 10.1. FISH
  • 10.2. IHC
  • 10.3. Next Generation Sequencing
  • 10.4. PCR

11. Oncology Precision Medicine Market, by Biomarker Type

  • 11.1. Epigenetic Testing
  • 11.2. Genetic Testing
  • 11.3. Protein Testing

12. Oncology Precision Medicine Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Clinics
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals

13. Oncology Precision Medicine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oncology Precision Medicine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oncology Precision Medicine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. F. Hoffmann-La Roche Ltd.
    • 16.3.3. Illumina, Inc.
    • 16.3.4. QIAGEN N.V.
    • 16.3.5. Danaher Corporation
    • 16.3.6. Agilent Technologies, Inc.
    • 16.3.7. Becton, Dickinson and Company
    • 16.3.8. Bio-Rad Laboratories, Inc.
    • 16.3.9. PerkinElmer, Inc.
    • 16.3.10. Guardant Health, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ONCOLOGY PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ONCOLOGY PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ONCOLOGY PRECISION MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IHC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY EPIGENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROTEIN TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. GCC ONC